地苯那明 | 51-50-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 地苯那明
• 英文名称: N,N-dibenzyl-2-chloroethanamine
• 英文别名: 2-N,N-dibenzylamino-ethyl chloride；Dibenamine；N-(2-chloroethyl)-N,N-dibenzylamine；N-(2-chloroethyl)dibenzylamine；N,N-dibenzylchloroethylamine
• CAS: 51-50-3
• 化学式: C₁₆H₁₈ClN
• mdl: MFCD00242994
• 分子量: 259.779
• InChiKey: GSLWSSUWNCJILM-UHFFFAOYSA-N

物化性质

• 熔点：
  192 °C
• 沸点：
  407.11°C (rough estimate)
• 密度：
  1.0738 (rough estimate)
• 颜色/状态：
  OILY LIQUID
• 稳定性/保质期：

  TURNS YELLOW ON STORAGE & DECOMP ON STANDING TO FORM SOLID POLYMERIC COMPD /CHLOROETHYLAMINES/

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

ADMET

毒理性

• 相互作用

阿托品似乎拮抗了双贝胺或“解阻滞”的作用。

...ATROPINE APPEARS TO ANTAGONIZE ACTION OF DIBENAMINE OR "DEBLOCK".

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

压力反应增加而未逆转通常出现在任何因素限制了肾上腺素能血管舒张能力的情况下，例如使用的拟交感胺（去甲肾上腺素、苯肾上腺素或其他具有最小β-肾上腺素能激动活性的制剂）或所使用的制剂。

REDN IN PRESSOR RESPONSE WITHOUT REVERSAL IS USUALLY SEEN WHEN CAPACITY FOR ADRENERGIC VASODILATATION IS LIMITED BY ANY FACTOR, FOR EXAMPLE, SYMPATHOMIMETIC AMINE USED (NOREPINEPHRINE, PHENYLEPHRINE, OR OTHER AGENTS WITH MINIMAL BETA-ADRENERGIC AGONISTIC ACTIVITY) OF PREPN EMPLOYED...

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

7%甲醛诱导的SC肉芽肿形成被肾上腺素显著抑制，而去甲肾上腺素略有抑制。二苯胺是一种较弱的实验性肉芽肿抑制剂。

FORMATION OF 7% FORMALADHYDE INDUCED SC GRANULOMA WAS GREATLY SUPPRESSED BY EPINEPHRINE & SLIGHTLY BY NOREPINEPHRINE. DIBENAMINE WAS A WEAKER EXPTL GRANULOMA SUPPRESSOR.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

一些肾上腺素能药物对小鼠自发活动的影响及对戊巴比妥亚催眠剂量增强作用的研究。双苯胺增强了戊巴比妥钠的作用。除布雷替尔外，所有药物均减少自发活动。

CENTRAL EFFECTS OF SOME ADRENOLYTICS ON SPONTANEOUS MOTILITY & ON POTENTIATION OF SUBHYPNOTIC DOSES OF SODIUM PENTOBARBITAL WERE STUDIED IN MICE. DIBENAMINE POTENTIATED THE ACTION OF SODIUM PENTOBARBITAL. ALL DRUGS, EXCEPT BRETYLIUM DECR SPONTANEOUS MOTILITY.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

多本胺.../刺激/中枢神经系统，导致恶心、呕吐、过度换气、运动兴奋性增加...抽搐，尤其是当相对大剂量的药物迅速静脉注射时。在人身上，可能会出现特征性的时间感知丧失。

DIBENAMINE.../STIMULATES/ CNS TO CAUSE NAUSEA, VOMITING, HYPERVENTILATION, MOTOR EXCITABILITY...CONVULSIONS, PARTICULARLY WHEN RELATIVELY LARGE DOSE IS RAPIDLY INJECTED IV. IN MAN, CHARACTERISTIC LOSS OF TIME PERCEPTION MAY OCCUR.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

GI肠道吸收不完全且有些随意...这些高度不稳定药物的代谢命运尚未完全了解。/卤代烷基胺肾上腺素能阻滞剂/

ABSORPTION FROM GI TRACT IS INCOMPLETE & SOMEWHAT CAPRICIOUS... THE METABOLIC FATE OF THESE HIGHLY UNSTABLE AGENTS IS POORLY UNDERSTOOD. /HALOALKYLAMINE ADRENERGIC BLOCKING AGENTS/

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  地苯那明 在 potassium tert-butylate 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 6.5h， 生成
  参考文献：
  名称：

  通过对氮杂环丁烷离子进行史蒂文斯重排合成 2-苯基-和 2,2-二芳基吡咯烷

  摘要：

  合成了一组在氮原子上被苄基或二苯甲基取代的氮杂环丁烷离子，以通过史蒂文斯重排描绘出它们扩环成 2-苯基-或 2,2-二芳基-吡咯烷的范围。尽管重排的区域选择性非常高，但在生成 2,3-二取代吡咯烷时，非对映选择性很低，但在一种情况下除外。主要的不希望有的副反应是导致环断裂的霍夫曼消除。

  DOI：

  10.1002/ejoc.201301536
• 作为产物：
  描述：

  N-(2-氯乙基)二苄胺 盐酸盐 在 sodium hydroxide 作用下， 以 水 、 乙酸乙酯 为溶剂， 以99.5%的产率得到地苯那明
  参考文献：
  名称：

  Reversal Agent and Linker Variants of Reversed Chloroquines: Activities against Plasmodium falciparum

  摘要：

  We have shown that "reversed chloroquine molecules" constructed from chloroquine-like and resistance "reversal-agent"-like cores can be powerful drugs against malaria (J. Med. Chem. 2006, 49, 5623-5625). Several reversed chloroquines are now presented that probe parameters governing the activities against chloroquine-resistant and chloroquine-sensitive malaria strains. The design is tolerant to linker and reversal agent changes, but it piperazinyl group adjacent to the quinoline, at least for the group Of Compounds studied here, may be detrimental.

  DOI：

  10.1021/jm900972u

文献信息

• Substituted triazole derivatives as oxytocin antagonists
  申请人：Brown Daniel Alan

  公开号：US20060160786A1

  公开（公告）日：2006-07-20

  The present invention relates to substituted triazoles of formula (I), uses thereof, processes for the preparation thereof and compositions containing said compounds. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction.

  本发明涉及公式（I）的取代三唑化合物，其用途，制备方法以及含有该化合物的组合物。这些抑制剂在包括性功能障碍在内的各种治疗领域具有用途。
• Derivatives of 3-aminopropane-1,2-diol
  申请人：Ciba-Geigy Corporation

  公开号：US04497813A1

  公开（公告）日：1985-02-05

  Derivatives of 3-aminopropane-1,2-diol of the formula ##STR1## in which Ar represents optionally substituted aryl, n represents the number 0 or 1, and alk represents alkylene having 2 to 5 carbon atoms, the nitrogen atom and the oxygen atom, or, if n is zero, the phenyl radical, being separated from one another by at least two carbon atoms, and R.sub.1 and R.sub.2, independently of one another, each represents hydrogen or lower alkyl, or together they represent lower alkylene, oxa-lower alkylene, thia-lower alkylene, aza-lower alkylene or N-lower alkyl-aza-lower alkylene, and salts of such compounds, processes for their manufacture, medicaments containing the new compounds and their use for the treatment of Angina pectoris and cardiac arrhythmia, and as blood pressure-reducing agents, as well as for the treatment of reactive or endogenic states of depression.

  3-氨基丙烷-1,2-二醇的衍生物的化学式为##STR1##其中Ar代表可选择取代的芳基，n代表数字0或1，alk代表具有2至5个碳原子的烷基，氮原子和氧原子，或者如果n为零，则苯基与彼此至少相隔两个碳原子，而R.sub.1和R.sub.2，彼此独立地，每个代表氢或较低的烷基，或者它们一起代表较低的烷基，氧杂环较低的烷基，硫杂环较低的烷基，氮杂环较低的烷基或N-较低烷基-氮杂环较低的烷基，以及这类化合物的盐，其制备方法，含有新化合物的药物以及它们用于治疗心绞痛和心律失常，以及作为降血压剂，以及用于治疗反应性或内源性抑郁状态。
• NPY antagonists: spiroisoquinolinone derivatives
  申请人：Bristol-Myers Squibb Company

  公开号：US06348472B1

  公开（公告）日：2002-02-19

  A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of spiroisoquinolinone derivatives of Formula I. As antagonists of NPY-induced feeding behavior, these compounds and known analogs are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.

  一系列非肽类NPY拮抗剂已经合成，由式I的螺环异喹啉酮衍生物组成。 作为NPY诱导的进食行为的拮抗剂，预计这些化合物和已知类似物将作为有效的厌食剂，在促进减重和治疗进食障碍方面发挥作用。
• Novel N-acylated heterocycles
  申请人：Recordati S.A.

  公开号：US20030162777A1

  公开（公告）日：2003-08-28

  Described are compositions comprising a muscarinic receptor antagonist and an N-acylated heterocycle derivative having affinity for serotonergic receptors, and enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts thereof. The combination of a muscarinic receptor antagonist and an N-acylated heterocycle, or an enantiomer, diastereoisomer, N-oxide, polymorph, solvate or pharmaceutically acceptable salt thereof, is useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT 1A receptors.

  描述了包含一种肌氨酸受体拮抗剂和一种对5-HT 1A 受体具有亲和力的N-酰化杂环衍生物的组合物，以及它们的对映体、二对映体、N-氧化物、多型体、溶剂合物和药用可接受盐。肌氨酸受体拮抗剂和N-酰化杂环，或其对映体、二对映体、N-氧化物、多型体、溶剂合物或药用可接受盐的组合，在治疗患有下尿路神经肌肉功能障碍和与5-HT 1A 受体相关疾病的患者中是有用的。
• New indazole and indolone derivatives and their use pharmaceuticals
  申请人：Allerton Norfor Charlotte Moira

  公开号：US20050267096A1

  公开（公告）日：2005-12-01

  The present invention provides for compounds of formula (I), which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. These compounds are useful for the treatment and/or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD; lack of interest in sex), female orgasmic disorder (FOD; inability to achieve orgasm); and male sexual dysfunction, in particular male erectile dysfunction (MED). Male sexual dysfunction as referred to herein is meant to include ejaculatory disorders such as premature ejaculation, anorgasmia (inability to achieve orgasm) or desire disorders such as hypoactive sexual desire disorder (HSDD; lack of interest in sex). These compounds are also useful in treating neuropsychiatric disorders and neurodegenerative disorders.

  本发明提供了一类多巴胺激动剂的化合物，具体来说是一类选择性作用于D3而非D2的激动剂。这些化合物可用于治疗和/或预防性功能障碍，例如女性性功能障碍（FSD），特别是女性性唤醒障碍（FSAD），性欲不振障碍（HSDD；对性欲缺乏兴趣），女性性高潮障碍（FOD；无法达到高潮）；以及男性性功能障碍，特别是男性勃起功能障碍（MED）。本文提到的男性性功能障碍包括射精障碍，如早泄，无法达到高潮的无性感（无法达到高潮）或性欲障碍，如性欲不振（HSDD；对性欲缺乏兴趣）。这些化合物还可用于治疗神经精神障碍和神经退行性疾病。